| Patient | Abraham Lincoln |
|---|---|
| Date of birth | 1994-02-12 |
| Identifiers | MRN HR-NI001-SYN; SSN (made up) 000-01-6683 |
| Document date | 2026-09-30 |
| Author | Elena Marquez, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Twelve-week depression care-plan review. [S]
Mr. Lincoln returns twelve weeks after starting sertraline 50 mg daily. He says he feels like himself again. He sleeps about seven hours, has kept up his court work and letters, and has added evening walks with a law colleague. His interest in his cases and his friends has returned, and his concentration is back to normal. He has had no side effects since the early nausea and still misses about one dose every two weeks. He has had no suicidal thoughts. The nurse telephone check planned for four weeks after his last visit did not take place. He asks how long he will need to keep taking the medicine. [S]
| Element | Detail |
|---|---|
| Interval change | Feels like himself; interest and concentration back to normal |
| Sleep | About seven hours a night |
| Medication tolerance | No adverse effects since the early nausea |
| Adherence | Misses about one dose every two weeks |
| Safety | No suicidal thoughts |
| PHQ-9 | 4, down from 14 |
| Patient question | How long to continue sertraline |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Good energy; weight up 1 kg since intake |
| Gastrointestinal | Negative | No nausea, diarrhea, or bleeding |
| Genitourinary | Negative | No sexual side effects |
| Neurological | Negative | No headache, tremor, or restlessness |
| Psychiatric | Negative | Mood good; sleeping well; no suicidal thoughts, elevated mood, or racing thoughts |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-06-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-30 | Body height | 193 | cm | S |
| 2026-09-30 | Body weight | 83 | kg | S |
| 2026-09-30 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-09-30 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-09-30 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-09-30 | Heart rate | 66 | /min | S |
| 2026-09-30 | Respiratory rate | 14 | /min | S |
| 2026-09-30 | Body temperature | 36.7 | Cel | S |
| 2026-09-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-30 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
Vital signs recorded on 2026-09-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, relaxed, and good-humored |
| Mental status | Alert and oriented; mood "good"; affect full and reactive; thought process linear; no suicidal ideation or psychotic features; insight and judgment good |
| Neurological | No tremor |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Major depressive disorder, single episode, moderate; synthetic modern diagnosis linked to documented low mood and its retrospective interpretation | active | provisional | F32.1 | S — Synthetic active diagnosis for the teaching episode; the historical depression label remains R. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 4, down from 14 at intake (71 percent): response and a remission-range score; the goal of below 5 is met |
| Survey | Interim PHQ-9 by nurse telephone check | At least monthly during acute treatment | Deferred | The telephone PHQ-9 planned at the six-week visit for about four weeks later was not made, so seven weeks passed without a score, a second deviation from the monthly cadence. No harm resulted: he improved steadily and reports no suicidal thoughts in the interval. Corrective action: continuation-phase PHQ-9s every two to four weeks are booked, the first at his preventive visit in about four weeks |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Safety plan reviewed and kept for the continuation phase |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | Misses about one dose every two weeks; no adverse effects |
| Medication safety | Tolerability check after a dose change | 1 to 2 weeks after each dose change | Not indicated | Dose unchanged; no increase needed |
| Medication safety | Continuation of sertraline at the remission dose | At least six months after remission | Up to date | Continue 50 mg daily for at least six months, then review tapering together |
| Examination | Weight, BMI, and blood pressure | With each tolerability check | Completed today | Weight 83.0 kg, up 1.0 kg since intake; BMI 22.3; blood pressure 114/72 mmHg |
| Examination | Mental status examination | Every visit | Completed today | Full, reactive affect; linear thinking; no suicidal ideation or psychotic features |
| Survey | Mood Disorder Questionnaire (bipolar screen) | Repeat if hypomanic features emerge | Not indicated | Bipolar disorder was not suspected at the psychiatry consultation, and no hypomanic features have appeared |
| Laboratory | Drug levels and metabolic laboratory monitoring | Lithium, valproate, carbamazepine, or second-generation antipsychotic therapy | Not indicated | Sertraline monotherapy needs no routine laboratory monitoring |
| Referral | Psychiatry review | If response stalls, after a failed dose increase, or for new risk | Up to date | Consultation completed six weeks ago; none of the criteria for another review are met |
| Referral | Psychotherapy for relapse prevention (CBT, interpersonal therapy, or mindfulness-based cognitive therapy) | In continuation for patients at high risk of relapse | Not indicated | A single uncomplicated episode in stable remission is not high risk; it stays available if he wants it |
| Self-management | Behavioral activation and sleep routine | Every visit | Completed today | Court work, letters, and evening walks continue; sleeping about seven hours |
Goal progress:
Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Adult preventive visit in about four weeks, with a PHQ-9. Depression review every two to four weeks in the continuation phase. Call the clinic or 988 at any time if his mood worsens. Next scheduled visit 2026-10-27: adult preventive visit. [S]